Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tiotropium and Salmeterol Fixed Dose Combination
NCT02254174Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tiotropium and salmeterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of salmeterol in blood plasma over the time interval from 0 extrapolated to infinity at 8 hours, Maximum measured concentration of salmeterol in blood plasma at 8 hours and 1 more. Started Mar 2006; status: completed.
02
Drugs
tiotropiumsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02254174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254174.